CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 78 enrolled
Drug / intervention
Influenza Vaccine +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05074303
NCT05074303Phase 2Completed
CompareCT.gov

Yeast-derived Beta-glucan Supplementation on Antibody Response Following Influenza Vaccination: A Randomized, Placebo-controlled Study (M-Unity)

University of Florida·interventional·Posted Oct 12, 2021·Updated Nov 6, 2025

In Brief

A Phase 2 clinical trial evaluating Influenza Vaccine, Beta-glucan, and 1 other intervention for Healthy Aging. Completed, enrolled 78 participants across 1 site.

Detailed Summary

This trial in healthy adults will determine the effects of beta-glucan, a dietary fiber supplement isolated from baker's yeast, on immune response to the influenza vaccine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Aging
CountriesUnited States
CollaboratorsDanstar Ferment AG

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedOct 12, 2021
Enrollment StartJul 18, 2022
Primary CompletionMar 1, 2024
Study CompletionAug 28, 2024
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.7 years ago

Interventions

Influenza Vaccinebiological

All subjects will receive the influenza vaccine.

Beta-glucandietary

2 - 250 mg capsules/day of beta-glucan derived from Baker's yeast

Placebodietary

2 - 250 mg capsules/day of cellulose